Author

Chandrakesan P

Director Research & Development, Wild Earth, Former Associate Professor, Member of Stepenson Cancer - Cited by 2,258 - Alternative food engineering - Stem cells and tissue engineering - Immuno-oncology - Cancer Stem cells and Resistant Therapies

Biography

Dr. Chandrakesan P  is an Associate professor in the Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. His study interests major on Medicine. In recent years, he has studied Cancer stem cell, Immuno-oncology. Currently, Dr. Chandrakesan is the author/editors/reviewer in several international journals. He published 29 articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Intestinal enteroendocrine lineage cells possess homeostatic and injury-inducible stem cell activity
KS Yan, O Gevaert, GXY Zheng, B Anchang, CS Probert, KA Larkin, ...Cell stem cell 21 (1), 78-90. e6, 2017201
309
2017
Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells
P Chandrakesan, J Yao, D Qu, R May, N Weygant, Y Ge, N Ali, ...Molecular Cancer 16 (1), 1-14, 2017201
94
2017
Alternative splice variants of DCLK1 mark cancer stem cells, promote self‐renewal and drug‐resistance, and can be targeted to inhibit tumorigenesis in kidney cancer
Y Ge, N Weygant, D Qu, R May, WL Berry, J Yao, P Chandrakesan, ...International journal of cancer 143 (5), 1162-1175, 2018201
50
2018
Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury
P Chandrakesan, R May, N Weygant, D Qu, WL Berry, SM Sureban, N Ali, ...Scientific reports 6 (1), 37667, 2016201
40
2016
Survival of patients with gastrointestinal cancers can be predicted by a surrogate microRNA signature for cancer stem–like cells marked by DCLK1 kinase
N Weygant, Y Ge, D Qu, JS Kaddis, WL Berry, R May, P Chandrakesan, ...Cancer research 76 (14), 4090-4099, 2016201
32
2016
Overexpression of DCLK1-AL increases tumor cell invasion, drug resistance, and KRAS activation and can be targeted to inhibit tumorigenesis in pancreatic cancer
D Qu, N Weygant, J Yao, P Chandrakesan, WL Berry, R May, K Pitts, ...Journal of oncology 2019, 2019201
30
2019
Tuft and cancer stem cell marker DCLK1: A new target to enhance anti-tumor immunity in the tumor microenvironment
Z Cao, N Weygant, P Chandrakesan, CW Houchen, J Peng, D QuCancers 12 (12), 3801, 2020202
27
2020
DCLK1 regulates tumor stemness and cisplatin resistance in non-small cell lung cancer via ABCD-member-4
J Panneerselvam, P Mohandoss, R Patel, H Gillan, M Li, K Kumar, ...Molecular Therapy-Oncolytics 18, 24-36, 2020202
22
2020
DCLK1-isoform2 alternative splice variant promotes pancreatic tumor immunosuppressive M2-macrophage polarization
P Chandrakesan, J Panneerselvam, R May, N Weygant, D Qu, WR Berry, ...Molecular cancer therapeutics 19 (7), 1539-1549, 2020202
18
2020
Inflammatory mediators and gut microbial toxins drive colon tumorigenesis by IL-23 dependent mechanism
J Panneerselvam, V Madka, R Rai, KT Morris, CW Houchen, ...Cancers 13 (20), 5159, 2021202
10
2021
Discovery and development of a novel mPGES-1/5-LOX dual inhibitor LFA-9 for prevention and treatment of chronic inflammatory diseases
NS Yarla, G Pathuri, H Gali, S Terzyan, J Panneerselvam, ...Journal of Inflammation Research, 1261-127, 2020202
8
2020
Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism
N Ali, CB Nguyen, P Chandrakesan, RF Wolf, D Qu, R May, T Goretsky, ...Scientific Reports 10 (1), 1057, 2020202
8
2020
Systemic delivery of CBT-15G DCLK1-targeted monoclonal antibody dramatically decreases tumorigenesis in a xenograft model of pancreatic cancer
N Weygant, D Qu, R May, P Chandrakesan, Y Ge, CD Ryan, G An, ...Cancer Research 76 (1_Supplement), 577-577, 2016201
4
2016
Bufalin Inhibits Tumorigenesis, Stemness, and Epithelial–Mesenchymal Transition in Colorectal Cancer through a C-Kit/Slug Signaling Axis
L Ding, Y Yang, Q Lu, D Qu, P Chandrakesan, H Feng, H Chen, X Chen, ...International Journal of Molecular Sciences 23 (21), 1335, 2022202
4
2022
Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma
EM Christman, P Chandrakesan, N Weygant, JT Maple, WM Tierney, ...Biomarker Research 7 (1), 1-5, 2019201
4
2019
Cancer cell of origin controls epithelial-to-mesenchymal transition in skin squamous cell carcinoma
P ChandrakesanStem Cell Investigation 4, 01701
2
2017
Knocking down the expression of DCLK1 reduces mammary tumor formation, tumor cell self-renewal and metastasis: DCLK1 a novel therapeutic target in breast cancer
Knocking down the expression of DCLK reduces mammary tumor formation, tumor cell self-renewal and metastasis: DCLK a novel therapeutic target in breast cancerP Chandrakesan, N Weygant, D Qu, W Berry, R May, N Ali, S Sureban, ...Cancer Research 76 (4_Supplement), 2493-2493, 20620
1
2016
Tamoxifen induces stem-like phenotypes and multidrug resistance by altering epigenetic regulators in ERα+ breast cancer cells
A Kalyanaraman, D Gnanasampanthapandian, P Shanmughan, ...Stem Cell Investigation 7, 2020202
1
2020
DCLK1 a novel therapeutic target in non-small cell lung cancer
DCLK a novel therapeutic target in non-small cell lung cancerP Chandrakesan, D Qu, R May, N Weygant, W Berry, N Ali, S Sureban, ...Cancer Research 77 (3_Supplement), 447-447, 20720
1
2017
LFA‐9, a Selective Inhibitor of Microsomal Prostaglandin Synthase‐1 and 5‐Lipoxygenase: Prevention of Inflammatory and Oncologic Diseases
LFA‐9, a Selective Inhibitor of Microsomal Prostaglandin Synthase‐ and 5‐Lipoxygenase: Prevention of Inflammatory and Oncologic DiseasesNS Yarla, G Pathuri, H Gali, J Panneerselvam, P Chandrakesan, V Madka, ...The FASEB Journal 34 (S), -, 2020202
1
2020

Referred From: https://scholar.google.com/citations?hl=en&user=rGAPsv0AAAAJ

Cited by
Citations 2258
h-index 29
i10-index 39
Recommended Journals
Open Access Journals